BioStem Technologies 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $7.6 million, compared with $7.9 million in the 2nd quarter of 2026.
- Hospital revenue increased 2% sequentially to $6.8 million from $6.7 million, while physician office revenue was $810,000, compared with $1.1 million in the prior quarter.
- Gross profit was $4.3 million, with a gross margin of 56%, compared with $4.8 million and 61% in the 2nd quarter; management attributed the decline primarily to higher transfer pricing under the BioTissue supply agreement.
- Operating expenses were $14.1 million, compared with $13.2 million in the prior quarter, and adjusted EBITDA loss was $6.4 million, compared with a $4.6 million loss.
- GAAP net loss was $11.4 million, or $0.64 per share, compared with a $9 million, or $0.52 per share, loss in the 2nd quarter.
- Cash and cash equivalents were $1 million as of September 30, 2026, compared with $7 million as of June 30, 2026; cash used in operating activities was $8.8 million in the 3rd quarter.
- Hospital revenue growth was strongest in July and September, which were the strongest hospital sales months since the acquisition closed; management said August was affected by the transition of services from BioTissue.
- From the 2nd quarter to the 3rd, accounts buying 2 or more product lines grew by 14%, and accounts buying 3 or more lines rose by more than 40%; customers buying more than one product account for more than half of revenue.
- The Vendale product family was added to existing GPO agreements with 2 major GPOs, described as the 2 largest group purchasing organizations in the United States.
- The company closed a private placement generating approximately $3 million in gross proceeds, with the potential for up to approximately $5.6 million in additional gross proceeds if accompanying warrants are exercised in full for cash.
- The company put in place a $40 million committed equity facility with Roth Capital Partners and had not sold any shares under it as of the call.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I will now hand the conference over to Philip Trip Taylor, Investor Relations.
Trip, please go ahead. Good afternoon, everyone, and thank you for joining our conference call to discuss BioStem's third quarter 2026 financial results and corporate highlights.
Leading the call today will be Jason Matuszewski, the company's Chair and Chief Executive Officer, and Brandon Poe, the company's Chief Financial Officer. Barry Hassett, the company's Chief Commercial Officer, will join for the question-and-answer session. Before we begin, I'd like to remind everyone that our remarks may contain forward-looking statements based on management's current expectations. These statements are subject to risks and uncertainties that are more fully described in our earnings press release issued today, our quarterly report on Form 10-Q for the quarter ended September 30, 2026, including under risk factors, and our filings with the U.S. Securities and Exchange Commission. Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements.
Finally, this call also includes reference to non-GAAP financial measures. A reconciliation to comparable GAAP measures and related information can be found in our earnings press release posted on the Investor Relations section of BioStem's website. With that, I'd now like to turn the call over to Jason Matuszewski.
Thank you, Trip, and good afternoon to everyone joining us. The third quarter marked BioStem's second full quarter operating as a predominantly hospital-focused business, and we continue to make meaningful progress in advancing our commercial strategy and strengthening our operational infrastructure. During the quarter, we once again drove sequential growth in hospital revenue while completing the implementation of our internal sales and operations management systems. This was a significant effort internally, and we want to thank our entire team for their continued dedication. Following this period of investment that has been required to build the new BioStem in 2026, our focus now is on executing a clear plan to accelerate our path to break even.
Today, I want to highlight four initiatives that define our direction moving forward: reducing our operating expenses, raising our gross margin by bringing Neox and Clarix manufacturing in-house, narrowing our adjusted EBITDA loss, and strengthening our balance sheet to fund that plan. As we look ahead, we remain committed to driving efficient growth by maximizing the potential of our commercial footprint and product portfolio while exercising disciplined expense management. This approach allows us to prioritize our highest impact growth opportunities while improving profitability and extending our cash runway as we build a sustainable business. in August, we commenced trading on the Nasdaq Capital Market, an achievement that has increased visibility of the company and broadened our institutional reach and expanded the range of capital alternatives available to the company. Following the uplist, we have taken several steps to strengthen our balance sheet, and that remains our top priority.
In September, we put in place a $40 million committed equity facility with Roth Capital Partners. We have not sold any shares under the facility to date and may not until early April of 2027, subject to certain conditions, including a $1 minimum share price. Over the long term, we believe the facility will provide an additional source of capital to strengthen our balance sheet and support our strategic priorities. Additionally, at the end of the quarter, we closed a private placement with multiple institutional investors, generating gross proceeds of approximately $3 million and the potential for up to approximately $5.6 million in additional gross proceeds from the exercise of accompanying warrants. Just after the quarter ended, Andrew Van Vurst, our Chief Operating Officer, and I each exercised options, which in total contributed approximately $1 million in cash to the company.
This investment reflects our conviction in BioStem's technology, our strategy, and our team, and the proceeds are intended to support working capital and maintain the inventory required to serve our customers. We are currently in the process of evaluating additional financing alternatives with a clear preference for non-dilutive structures. More broadly, our objective is to accelerate our path to profitability and to extend our cash runway through efficient growth and disciplined expense reduction. We are accelerating real changes to our cost structure and expect the cost reduction plan we are evaluating to reduce our annual cash operating expenses by approximately $10 million-$12 million. Our strategy is focused on removing spending from areas that are not directly contributing to revenue generation, which Brandon will walk through in a few minutes.
As part of these cost reduction and cash preservation efforts, Andrew and I have offered to reduce our annual cash salaries to $250,000 in 2027 and to receive the balance of our salaries in BioStem stock, subject to board approval. Like our option exercises, this reflects our conviction in the company, and it lowers our cash expenses at a time when it matters most. Moving forward, we are focusing our resources on initiatives that have a direct impact on revenue generation, driving revenue growth, and expediting the path to profitability. Critical to this effort will be to transition Neox and Clarix production into our Pompano Beach facility. We expect products we manufacture to carry a meaningful higher gross margin, and our goal is clear: move toward profitability as quickly as possible while maintaining sustainable revenue growth. We are simultaneously working to reduce the near-term demands on our cash.
We are in active discussions with BioTissue to restructure the terms of the clearance payment, which remains outstanding, with the goal of lowering our near-term cash obligations. We look forward to sharing more details once those discussions are complete. In the meantime, supply of Neox and Clarix continues without interruption. Now, turning to the quarterly results. During the quarter, we increased hospital revenue sequentially to $6.8 million. This increase was driven by strength in July and September, which represented our strongest hospital sales months since the close of the acquisition. I will now provide updates on our strategy to prioritize resources to drive growth in the most efficient way possible. Effective at the beginning of August, the transition services agreement with BioTissue concluded, and responsibility for sales logistics, operational support, invoicing, collections, and inventory management fully transferred to BioStem, giving us better control over working capital.
With the transition now complete, we have full ownership of the systems and data that underpin our commercial organization. This was not a small task, and I'm proud of our team for integrating several complex systems in such a short period of time. Our customer relationship management platform is now live and integrated with our enterprise resource planning system. We will use this available data to more precisely target our highest value customers. Specifically, we will be able to leverage our commercial infrastructure to drive growth and improve productivity without proportional increase in cost. After a learning curve of just over a month, the organization had fully adapted by September, and we now have dramatically improved insight into account activity, inventory, and ordering behavior than we had before the transition.
Looking at our commercial progress, we continue to drive adoption of our product portfolio, including the Neox, Clarix, and VENDAJE brands in the hospital market. Our commercial strategy in the hospital channel remains centered on two complementary objectives: deepening utilization within facilities where our products are already approved and expanding our footprint with the addition of new accounts. A significant portion of our growth opportunity lies within the hospitals we already serve. Having already made the investments required to establish contract access and relationships with key customers, we are now well-positioned to expand utilization within these facilities at a meaningfully lower incremental cost. In September, the VENDAJE product family was added to our existing GPO agreements with two major GPOs, the two largest group purchasing organizations in the U.S.
These additions represent the first GPO coverage for the VENDAJE product family and allow clinicians across those GPO member facilities to procure VENDAJE through established contracting channels. As a result, deepening penetration within our existing customer base through GPO coverage expansion represents one of the most efficient avenues for growth available to BioStem. We remain pleased with the progress of our sales organization as we continue to focus on our most productive territories to gain new accounts. We are seeing that our broad product portfolio and GPO access continues to attract new customers and expand our account base. Just as important, existing customers are expanding their use of our portfolio. From the second quarter to the third, the number of accounts buying two or more of our product lines grew by 14%. Customers buying three or more lines rose by more than 40%. That depth matters. Customers who buy across our portfolio, meaning buy more than one product, account for more than half of our revenue.
These metrics demonstrate that our commercial strategy is working and that clinicians are seeing value for their patients across a variety of specialties and procedures. We believe these metrics will continue to trend in a positive direction. Clinical evidence remains foundational to our approach in wound care. Our VLU study is on track, and we are scheduled to report top-line results at the Innovations in Wound Healing meeting in early December. This clinical evidence is helping to drive physician adoption and deepen hospital penetration, and we believe its importance will only increase as coverage and product selection decisions become more evidence-driven. Our field organization integrates this evidence into every customer engagement, and we believe that it adds another point of leverage for our technology.
With the combination of targeted execution around key use cases, strategic accounts, clinical evidence, new products coming onto our GPO agreements, we believe we are well-positioned to broaden adoption of our portfolio and support our growth expectations over the coming years. Now, an update on the technology transfer of Neox and Clarix. The transfer of Neox and Clarix manufacturing to our Pompano Beach facility remains a significant value driver for BioStem. Bringing production in-house is expected to deliver significant improvement in gross margin and cash generation, and our existing infrastructure allows us to accomplish this with modest capital investment. We remain on track to complete the tech transfer and begin in-house production in the first half of 2027, subject to process validation and applicable regulatory requirements. In the interim, BioTissue continues to manufacture these products on our behalf under our manufacturing and supply agreement.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
